RU2010136988A - Антигенсвязывающие полипептиды против дегенерации хряща - Google Patents

Антигенсвязывающие полипептиды против дегенерации хряща Download PDF

Info

Publication number
RU2010136988A
RU2010136988A RU2010136988/10A RU2010136988A RU2010136988A RU 2010136988 A RU2010136988 A RU 2010136988A RU 2010136988/10 A RU2010136988/10 A RU 2010136988/10A RU 2010136988 A RU2010136988 A RU 2010136988A RU 2010136988 A RU2010136988 A RU 2010136988A
Authority
RU
Russia
Prior art keywords
binding polypeptide
antigen binding
polypeptide according
antigen
polypeptide
Prior art date
Application number
RU2010136988/10A
Other languages
English (en)
Russian (ru)
Inventor
Дэвид УРЕХ (CH)
Дэвид УРЕХ
Петер ЛИХТЛЕН (CH)
Петер ЛИХТЛЕН
Original Assignee
Деленекс Терапьютикс Аг (Ch)
Деленекс Терапьютикс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Деленекс Терапьютикс Аг (Ch), Деленекс Терапьютикс Аг filed Critical Деленекс Терапьютикс Аг (Ch)
Publication of RU2010136988A publication Critical patent/RU2010136988A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2010136988/10A 2008-02-05 2009-02-05 Антигенсвязывающие полипептиды против дегенерации хряща RU2010136988A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2631708P 2008-02-05 2008-02-05
US61/026,317 2008-02-05
US8887608P 2008-08-14 2008-08-14
US61/088,876 2008-08-14

Publications (1)

Publication Number Publication Date
RU2010136988A true RU2010136988A (ru) 2012-03-20

Family

ID=40568129

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010136988/10A RU2010136988A (ru) 2008-02-05 2009-02-05 Антигенсвязывающие полипептиды против дегенерации хряща

Country Status (10)

Country Link
US (1) US20110002927A1 (OSRAM)
EP (1) EP2240515A1 (OSRAM)
JP (1) JP2011510667A (OSRAM)
CN (1) CN101939335B (OSRAM)
AU (1) AU2009212079B2 (OSRAM)
BR (1) BRPI0907485A2 (OSRAM)
CA (1) CA2712965A1 (OSRAM)
IL (1) IL206720A0 (OSRAM)
RU (1) RU2010136988A (OSRAM)
WO (1) WO2009097704A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013540757A (ja) 2010-09-24 2013-11-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド カプセル化された作用物質の放出を制御する能力を有するナノ構造ゲル
CN104231086B (zh) * 2013-08-27 2019-12-13 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
JP6220894B2 (ja) * 2013-12-13 2017-10-25 有限会社マーキュリーアセットマネジメント 関節軟骨の変性部位の可視化用組成物
WO2017193139A1 (en) * 2016-05-06 2017-11-09 The Brigham And Women's Hospital, Inc. Binary self assembled gels for controlled delivery of encapsulated agents to cartilage
EP3863602A1 (en) 2018-10-11 2021-08-18 Alivio Therapeutics, Inc. Non-injectable hydrogel formulations for smart release

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
DK2390267T3 (da) * 2005-06-07 2013-08-26 Esbatech A Novartis Co Llc Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
PT2046382T (pt) * 2006-07-10 2016-11-23 Esbatech Alcon Biomed Res Unit Anticorpos scfv que atravessam as camadas epitelial e/ou endotelial

Also Published As

Publication number Publication date
CN101939335A (zh) 2011-01-05
CN101939335B (zh) 2015-02-11
US20110002927A1 (en) 2011-01-06
IL206720A0 (en) 2010-12-30
BRPI0907485A2 (pt) 2015-08-04
CA2712965A1 (en) 2009-08-13
AU2009212079A1 (en) 2009-08-13
AU2009212079B2 (en) 2012-08-30
EP2240515A1 (en) 2010-10-20
WO2009097704A1 (en) 2009-08-13
JP2011510667A (ja) 2011-04-07

Similar Documents

Publication Publication Date Title
AU2014337367B2 (en) Peptidic chimeric antigen receptor T cell switches and uses thereof
US20180118808A1 (en) SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
RU2012143793A (ru) Биспецифические двухвалентные антитела анти-vegf/анти-ang-2
JP2020536109A5 (OSRAM)
RU2013141078A (ru) Одновалентные антигенсвязывающие белки
RU2012129735A (ru) Антитела к her3 и их применения
RU2011142184A (ru) Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EA031209B9 (ru) Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
US9757473B2 (en) Cell-penetrating peptide and conjugate comprising same
SI2542257T1 (en) Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
JP2017534259A5 (OSRAM)
EP3587440B1 (en) Human pd-l1 high-protein-affinity peptide and use thereof
NZ603161A (en) Superior efficacy of cd37 antibodies in cll blood samples
RU2010136988A (ru) Антигенсвязывающие полипептиды против дегенерации хряща
IL273578B1 (en) Antibodies targeting pdl1 and methods of use thereof
US20200078472A1 (en) Self assembling molecules for targeted drug delivery
CN118251406A (zh) 血管活性肠肽(vip)受体拮抗剂
EP3313871A1 (en) Proteins comprising a mutated lair-1 fragment and uses thereof
CN117730143A (zh) 通过缀合的n-末端甘氨酸修饰的细胞及其用途
WO2021228052A1 (zh) 生物大分子靶向特异性补体抑制剂及其制备方法与应用
JP2011510667A5 (OSRAM)